/5
0 avis
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
Archive ouverte
International audience
Consulter en ligne
Chargement des enrichissements...